LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today reported financial results and operational highlights for the quarter ended September 30, 2016.
Category: Business
Ocular Therapeutix™ Reports Third Quarter 2016 Financial Results and Provides Corporate Update
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September 30, 2016 and provided a general business update. “Following productive discussions with the FDA, we are preparing for the resubmission of our NDA for DEXTENZA™ for post-surgical ocular pain by the end of the year,
Ophthotech Reports Third Quarter 2016 Financial and Operating Results
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced financial results for the third quarter ended September 30, 2016 and provided an update on the Company’s business and product development programs.
Dicerna Reports Third Quarter 2016 Financial and Operational Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna Pharmaceuticals today reported financial and operational results for the third quarter ended September 30, 2016.
Pixium Vision Announces the First Successful Implantation and Activation of IRIS® II, 150 Electrode Bionic Vision System, in the UK
PARIS & LONDON–(BUSINESS WIRE)–Regulatory News: Pixium Vision (Paris:PIX) (FR0011950641 – PIX, “Pixium”), a company developing innovative bionic vision systems with the intention to allow patients who have lost their sight to lead more independent lives, announces the first successful implantation and activation of IRIS® II in the UK. This epi-retinal implant with 150 electrodes is intended for patients who have lost sight as a result of retinitis pigmentosa (RP). The first implant of IRIS® I
Pixium Vision annonce la réussite de l’implantation et l’activation du premier patient au Royaume-Uni avec son système de vision bionique IRIS®II doté de 150 électrodes
PARIS & LONDRES–(BUSINESS WIRE)–Regulatory News : Pixium Vision (Paris:PIX) (FR0011950641 – PIX), société qui développe des systèmes de vision bionique innovants en vue de permettre aux patients ayant perdu la vue de vivre de façon plus autonome, annonce l’implantation et l’activation réussies du premier patient ayant perdu la vue suite à une rétinite pigmentaire, avec son système bionique IRIS® II, doté d’un implant épi-rétinien explantable de 150 électrodes, au Royaume-Uni. Cette première i
Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting infl…
Beaver-Visitec International Names Dana G. Mead Jr. President and CEO
WALTHAM, Mass.–(BUSINESS WIRE)–Beaver-Visitec International (“BVI”) today announced that it has named Dana G. Mead Jr. as President and Chief Executive Officer.
Aerie Pharmaceuticals to Participate in Three Investor Conferences in November
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that company managemen…
NovaBay Pharmaceuticals to Hold Third Quarter 2016 Conference Call on November 10
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report third quarter 2016 financial results after market close on Thursday, November 10. Management will hold an investment community conference call that day to discuss financial results and provide a Company update. DATE: Thursday,
Ocular Therapeutix™ to Hold Third Quarter 2016 Financial Results Conference Call on Wednesday, November 9, 2016
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report t…
Second Sight Announces Final CMS Hospital Outpatient Payment Rate for 2017 and Two New CPT Codes for Programming the Argus II Retinal Prosthesis System
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight”), a developer, manufacturer and marketer of implantable visual prosthetics that provide a form of useful vision to blind patients, today announced that the Centers for Medicare & Medicaid Services (CMS) finalized its Medicare hospital outpatient payment rate of $150,000.50 for calendar year 2017. The payment for the surgical procedure includes the cost of the Argus® II Retinal Prosthesis Syste
ACADIA Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 7, 2016
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today ann…
Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that the Phase 2b study results of Fovista®, the Company’s anti-PDGF agent, have been published online in Ophthalmology®, the journal of the American Academy of Ophthalmology.
iStent® Trabecular Micro-Bypass Stent Reduced IOP and Medication Use in Predominately Hispanic Glaucoma Patient Population, According to Published Study
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals Successfully Regains Compliance with NYSE Continued Listing Requirements
Acucela Issues Notice of Listing Approval of Kubota Pharmaceutical Holdings
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (Tokyo:4589) (the “Company”), a clinical-stage ophthalmology company that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, hereby gives notice that the merger agreement regarding its proposed redomicile transaction was adopted at the Annual Meeting of Shareholders of the Company held on October 18, 2016 Pacific Time in Seattle, Washington. Upon the completion of the mer
VTI Introduces the NaturalVue® Multifocal QuickStart Calculator
ALPHARETTA, Ga.–(BUSINESS WIRE)–The NaturalVue Multifocal QuickStart Calculator provides the optimal starting lens powers & only requires the patient’s best corrected spectacle refraction and vertex distance. Download the app now.
Omeros Announces $125 Million New Credit Facility
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that it has entered into a senior credit facility with CRG LP, a healthcare-focused investment firm, to retire the company’s existing credit facility, minimizing restricted cash requirements and providing additional working capital for its advancing pipeline. The new credit facility consists of an $80 million term loan to be drawn by the company within ten business days and the ability, subject to the satisfaction of ce
Global Eyewear Market with Focus on Luxury Sunglass 2016-2020: Industry Analysis & Outlook Featuring Essilor, Grand Vision, Luxottica & Safilo Group – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Global Eyewear Market with Focus on Luxury Sunglass: Industry Analysis & Outlook (2016-2020)” report to their offering. The global eyewear market can be segmented into contact lenses and spectacles. Further, the spectacles market can be sub-segmented into: spectacle frames, spectacle lenses, and sunglasses. In spite of weakening growth, the eyewear industry remains strong, with factors such as increasing myopia